CCR2 and cancer: We performed Elispot assays for IFNγ secreting capacity of CD8+ T cells derived from the draining lymph nodes of tumor-bearing WT or CCR2−/− mice 7 days post-IR, using MC38 cancer cells as sources of tumor antigen.